SANTA CLARA, Calif., Nov. 6 /PRNewswire/ -- Lumenis(R) Ltd. a global developer, manufacturer and marketer of laser, light-based and radiofrequency devices for ophthalmic, surgical and aesthetic applications, announced today that it will introduce four new ophthalmic lasers and delivery devices on November 8th at the American Academy of Ophthalmology (AAO) Annual Meeting in Atlanta, Georgia.
Dov Ofer, Lumenis’ President and Chief Executive Officer stated: “Lumenis is proud to be yet again at the forefront of ophthalmic laser technology with the introduction of the Selecta(R) family of ophthalmic lasers, the Novus(R) Spectra(TM) Dual-Port Photocoagulator and the LumeProbe(TM) comprehensive family of premium endo photocoagulation laser probes. This industry-leading achievement stems from Lumenis’ 40-year history of ophthalmic laser innovation. In 1970, we were the first company to introduce a laser in this field; since then, we have followed with a series of additional sight-preserving milestones, including the first laser photocoagulator, laser indirect ophthalmoscope, multicolor photocoagulator, photodynamic therapy laser, the revolutionary Selective Laser Trabeculoplasty (SLT) system and solid state multicolor laser.”
“At this year’s AAO Meeting, we simply continue this long-standing tradition as we proudly showcase the newest additions to our existing and already robust product portfolio of ophthalmic lasers - a new and complete set of ophthalmic laser solutions. Our Selecta family of lasers for the ophthalmic practice offers it all - from ultimate simplicity, to comprehensive choice of therapy with maximum flexibility. Our new laser delivery devices are specifically designed to provide superior performance, as well as improve physician comfort during procedures,” said Dov Ofer.
“Today, Lumenis also further expands its capabilities in the Retina segment with the introduction of the LumeProbe product family,” said Gideon (Gidi) Sturlesi, Corporate Vice President & acting General Manager of Lumenis Vision, the ophthalmic business unit of Lumenis. “Our newest line of premium ophthalmic endo-photocoagulation laser probes was designed with the retina specialist in mind, featuring advanced manufacturing practices, unique fiber polishing techniques and uncompromising quality assurance methodologies that deliver product performance & reliability second to none.”
“Based on over 25 years of laser probes manufacturing expertise, the LumeProbe product family was designed to deliver laser energy in the safest and most efficient manner, guaranteeing optimal clinical outcome for all relevant viteroretinal indications,” concluded Mr. Sturlesi.
New Product Introduction:
Ophthalmologists attending the 2008 AAO meeting and seeking ultimate simplicity, maximum flexibility, comprehensive choice of therapy and complete operating room solutions will have access to Lumenis’ new technology at AAO booth # 2021, November 8th through November 11th.
About the American Academy of Ophthalmology and 2008 Annual Meeting
The American Academy of Ophthalmology is the largest national membership association of ophthalmologists, medical doctors who provide comprehensive eye care, including medical, surgical and optical care. More than 90 percent of practicing U.S. ophthalmologists are Academy members, and the Academy has more than 7,000 international members. The Academy’s 112th Annual Meeting from November 8 to 11 will be in Atlanta, GA, at the World Congress Center. The 2008 Annual Meeting program will highlight how technology advances are improving patient care. For more information about the AAO and Annual Meeting, log on to http://www.aao.org
About Lumenis
Lumenis is a leading medical device company with over 850 employees worldwide. The Company invests heavily in R&D and holds a leading position in the markets in which it serves. Lumenis has over 250 patents worldwide, over 75 FDA clearances, worldwide presence in over 100 countries, and an installed base of over 70,000 systems.
www.lumenis.com
Lumenis(R) is a registered trademark of Lumenis Ltd.
CONTACT: Michelle Maydan, Director of Corporate Communications, Lumenis,
1-866-569-0597, +972-4-959-9004
Web site: http://www.aao.org/
http://www.lumenis.com/
